"MetCool ACS"- Metformin "Cooling" Effect on metformin-naive Patients Treated with PCI because of Acute Coronary Syndrome

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516589-13-00

Acronym

MC-ACS01-2020

Enrollment

1000

Registered

2024-11-18

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute coronary syndrome

Brief summary

The need to perform unplanned PCI or CABG after successful last stage of full revascularization because of ACS

Detailed description

Cardiac death after successful final stage of revascularization due to ACS in the 30-month follow-up period, Death from any cause after successful final stage of revascularization due to ACS in the 30-month follow-up period, Non-fatal myocardial infarction after successful final stage of revascularization due to ACS in the 30-month follow-up period, Non-fatal stroke after successful final stage of revascularization due to ACS in the 30-month follow-up period

Interventions

DRUGMETFORMIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The need to perform unplanned PCI or CABG after successful last stage of full revascularization because of ACS	—

Secondary

Measure	Time frame
Cardiac death after successful final stage of revascularization due to ACS in the 30-month follow-up period, Death from any cause after successful final stage of revascularization due to ACS in the 30-month follow-up period, Non-fatal myocardial infarction after successful final stage of revascularization due to ACS in the 30-month follow-up period, Non-fatal stroke after successful final stage of revascularization due to ACS in the 30-month follow-up period	—

Measure

Time frame

—

Countries

Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026